Back to School: How biopharma can reboot drug development. Access exclusive analysis here

One miss

One miss

Company 2Q EPS est 2Q EPS actual Outcome Chg from 2Q02 (D) 7/25 cls Wk chg % chg Mkt cap chg ($M) 7/25 mkt cap ($M)
Affymetrix (AFFX) $0.03 $0.09 Beat by $0.06 200% $23.50 $2.43 12% $143 $1,379
2Q03 product-related revenues increased 8% to $63.2M. However, total revenues slipped 3% to $68.6M due in part to a falloff in sales to its Perlegen spinoff, which AFFX said was in line with contractual obligations. AFFX said it expects FY03 GAAP EPS of $0.20-$0.25 on $280M in product and product-related revenues. AFFX, which only provided U.S. GAAP EPS figures, said the analyst consensus is a mix of GAAP and pro forma EPS.
Amgen (AMGN) $0.46 $0.49 Beat by

Read the full 1244 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE